AbbVie Reports Results of Rinvoq (upadacitinib) in P-III SELECT-PsA 2 Study for Psoriatic Arthritis

AbbVie Reports Results of Rinvoq (upadacitinib) in P-III SELECT-PsA 2 Study for Psoriatic Arthritis

Shots:

  • The P-III SELECT-PsA 2 study involves assessing of Rinvoq (15/30mg) vs PBO in adult patients with active psoriatic arthritis who have responded inadequately to one or more biologic disease-modifying anti-rheumatic drugs (bDMARDs)
  • The P-III SELECT-PsA 2 study results: @12wks. patients achieved ACR20 (57%/64% vs 24%), ACR 50(32%/38% vs 5%), ACR 70 (9%/17% vs 0.5%); @16wks. patients achieved PASI 75 (52%/57% vs 16%); @24wks. patients achieved minimal disease activity (25%/29% vs 3%); safety profile was consistent with the previous studies with no new safety risks detected
  • RINVOQ is a selective and reversible JAK inhibitor, developed by Amgen, currently being studied for once-daily therapy in psoriatic arthritis and multiple immune-mediated diseases

Click here to­ read full press release/ article | Ref: AbbVie | Image:  Science